{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:28:23Z","timestamp":1786663703040,"version":"build-2736575974"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41391-025-01071-7","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T12:21:05Z","timestamp":1766492465000},"page":"516-528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-4873","authenticated-orcid":false,"given":"Jennifer","family":"Le Guevelou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9883","authenticated-orcid":false,"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ferrario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-9319","authenticated-orcid":false,"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4883-1781","authenticated-orcid":false,"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uulke A.","family":"Van der Heide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Draulans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarad","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2203-4848","authenticated-orcid":false,"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"1071_CR1","first-page":"02254","volume":"S0302-2838","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;S0302-2838:02254\u20131.","journal-title":"Eur Urol"},{"key":"1071_CR2","doi-asserted-by":"publisher","first-page":"LBA259","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA259","volume":"42","author":"C Hennequin","year":"2024","unstructured":"Hennequin C, Sargos P, Roca L, Silva M, Latorzeff I, Peiffert D, et al. Long-term results of dose escalation (80 vs. 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial. J Clin Oncol. 2024;42:LBA259\u2013LBA259.","journal-title":"J Clin Oncol"},{"key":"1071_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.clon.2012.05.002","volume":"24","author":"G Bauman","year":"2012","unstructured":"Bauman G, Rumble RB, Chen J, Loblaw A, Warde P. Members of the IMRT Indications Expert Panel. Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol R Coll Radiol G B. 2012;24:461\u2013473.","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"1071_CR4","doi-asserted-by":"publisher","first-page":"e0154499","DOI":"10.1371\/journal.pone.0154499","volume":"11","author":"T Yu","year":"2016","unstructured":"Yu T, Zhang Q, Zheng T, Shi H, Liu Y, Feng S, et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PloS ONE. 2016;11:e0154499.","journal-title":"PloS ONE"},{"key":"1071_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.radonc.2019.10.017","volume":"142","author":"J Murray","year":"2020","unstructured":"Murray J, Griffin C, Gulliford S, Syndikus I, Staffurth J, Panades M, et al. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020;142:62\u201371.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"1071_CR6","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ijrobp.2018.07.2006","volume":"102","author":"R de Crevoisier","year":"2018","unstructured":"de Crevoisier R, Bayar MA, Pommier P, Muracciole X, P\u00eane F, Dudouet P, et al. Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial. Int J Radiat Oncol Biol Phys. 2018;102:1420\u20131429.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR7","doi-asserted-by":"crossref","unstructured":"Le Gu\u00e9velou J, Murthy V, Zilli T, Nicosia L, Bossi A, Bokhorst LP et al. \u00abAugmented radiotherapy\u00bb in the management of high-risk prostate cancer (PCa): a systematic review. Crit Rev Oncol Hematol 2025;207:104623.","DOI":"10.1016\/j.critrevonc.2025.104623"},{"key":"1071_CR8","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","volume":"82","author":"R Miralbell","year":"2012","unstructured":"Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-Fractionation Sensitivity of Prostate Cancer Deduced From Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: \u03b1\/\u03b2 = 1.4 (0.9\u20132.2) Gy. Int J Radiat Oncol. 2012;82:e17\u2013e24.","journal-title":"Int J Radiat Oncol"},{"key":"1071_CR9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17:1047\u20131060.","journal-title":"Lancet Oncol"},{"key":"1071_CR10","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu C-S, Martin JM, Supiot S, Chung PWM, et al. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:1884\u20131890.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1071_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(25)00034-8","volume":"26","author":"AU Kishan","year":"2025","unstructured":"Kishan AU, Sun Y, Tree AC, Hall E, Dearnaley D, Catton CN, et al. Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium. Lancet Oncol. 2025;26:459\u2013469.","journal-title":"Lancet Oncol"},{"key":"1071_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Smeenk RJ, et al. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. J Clin Oncol. 2021;39:787\u2013796.","journal-title":"J Clin Oncol"},{"key":"1071_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"391","author":"N Van As","year":"2024","unstructured":"Van As N, Griffin C, Tree A, Patel J, Ostler P, Van Der Voet H, et al. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. N Engl J Med. 2024;391:1413\u20131425.","journal-title":"N Engl J Med"},{"key":"1071_CR14","doi-asserted-by":"crossref","unstructured":"Tree AC, Hinder V, Chan A, Tolan S, Ostler P, Van Der Voet H et al. Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 2025;26:936\u2013947.","DOI":"10.1016\/S1470-2045(25)00205-0"},{"key":"1071_CR15","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","volume":"35","author":"G Arcangeli","year":"2017","unstructured":"Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari MG, Sanguineti G, et al. Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial. J Clin Oncol. 2017;35:1891\u20131897.","journal-title":"J Clin Oncol"},{"key":"1071_CR16","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.ijrobp.2009.12.045","volume":"79","author":"G Arcangeli","year":"2011","unstructured":"Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari MG, et al. Acute and Late Toxicity in a Randomized Trial of Conventional Versus Hypofractionated Three-Dimensional Conformal Radiotherapy for Prostate Cancer. Int J Radiat Oncol. 2011;79:1013\u20131021.","journal-title":"Int J Radiat Oncol"},{"key":"1071_CR17","doi-asserted-by":"publisher","unstructured":"Sanmamed N, Dayes I, Catton C, Liu A, Supiot S, Lukka H et al. Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer. Eur Urol Oncol 2025;S2588931125000951 https:\/\/doi.org\/10.1016\/j.euo.2025.03.017.","DOI":"10.1016\/j.euo.2025.03.017"},{"key":"1071_CR18","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1200\/JCO.23.02445","volume":"42","author":"WR Lee","year":"2024","unstructured":"Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2024;42:2377\u20132381.","journal-title":"J Clin Oncol"},{"key":"1071_CR19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1001\/jamaoncol.2018.6752","volume":"5","author":"DW Bruner","year":"2019","unstructured":"Bruner DW, Pugh SL, Lee WR, Hall WA, Dignam JJ, Low D, et al. Quality of Life in patients with low-risk prostate cancer treated with hypofractionated vs. conventional radiotherapy: a phase 3 randomized clinical trial. JAMA Oncol. 2019;5:664.","journal-title":"JAMA Oncol"},{"key":"1071_CR20","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijrobp.2022.07.2323","volume":"114","author":"TM Niazi","year":"2022","unstructured":"Niazi TM, Nabid A, Malagon T, Bettahar R, Vincent LS, Martin AG, et al. Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 7-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial. Int J Radiat Oncol. 2022;114:S3.","journal-title":"Int J Radiat Oncol"},{"key":"1071_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.eururo.2024.08.032","volume":"87","author":"T Niazi","year":"2025","unstructured":"Niazi T, Nabid A, Malagon T, Tisseverasinghe S, Bettahar R, Dahmane R, et al. Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial. Eur Urol. 2025;87:314\u2013323.","journal-title":"Eur Urol"},{"key":"1071_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. The Lancet. 2019;394:385\u2013395.","journal-title":"The Lancet"},{"key":"1071_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","volume":"22","author":"P Fransson","year":"2021","unstructured":"Fransson P, Nilsson P, Gunnlaugsson A, Beckman L, Tavelin B, Norman D, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol. 2021;22:235\u2013245.","journal-title":"Lancet Oncol"},{"key":"1071_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijrobp.2020.01.022","volume":"107","author":"E Rasmusson","year":"2020","unstructured":"Rasmusson E, Gunnlaugsson A, Wieslander E, H\u00f6glund P, Widmark A, Fransson P, et al. Erectile Dysfunction and Absorbed Dose to Penile Base Structures in a Randomized Trial Comparing Ultrahypofractionated and Conventionally Fractionated Radiation Therapy for Prostate Cancer. Int J Radiat Oncol. 2020;107:143\u2013151.","journal-title":"Int J Radiat Oncol"},{"key":"1071_CR25","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.euo.2021.07.005","volume":"4","author":"JN Staffurth","year":"2021","unstructured":"Staffurth JN, Haviland JS, Wilkins A, Syndikus I, Khoo V, Bloomfield D, et al. Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK\/06\/016). Eur Urol Oncol. 2021;4:980\u2013992.","journal-title":"Eur Urol Oncol"},{"key":"1071_CR26","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1200\/JCO.2018.77.9868","volume":"36","author":"KE Hoffman","year":"2018","unstructured":"Hoffman KE, Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ, et al. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. J Clin Oncol. 2018;36:2943\u20132949.","journal-title":"J Clin Oncol"},{"key":"1071_CR27","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/COC.0000000000000325","volume":"41","author":"KE Hoffman","year":"2018","unstructured":"Hoffman KE, Skinner H, Pugh TJ, Voong KR, Levy LB, Choi S, et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. Am J Clin Oncol. 2018;41:558\u2013567.","journal-title":"Am J Clin Oncol"},{"key":"1071_CR28","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1200\/JCO.19.01485","volume":"38","author":"Avkshtol","year":"2020","unstructured":"Avkshtol, Ruth V, Ross KJ, Hallman MA EA, Greenberg RE, Price RA, et al. Ten-year update of a randomized, prospective trial of conventional fractionated versus moderate hypofractionated radiation therapy for localized prostate cancer. J Clin Oncol. 2020;38:1676\u20131684.","journal-title":"J Clin Oncol"},{"key":"1071_CR29","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.ijrobp.2016.12.034","volume":"97","author":"Shaikh","year":"2017","unstructured":"Shaikh, Li T, Handorf T, Johnson EA, Wang ME, Hallman MA LS, et al. Long-Term patient-reported outcomes from a phase 3 randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. Int J Radiat Oncol. 2017;97:722\u2013731.","journal-title":"Int J Radiat Oncol"},{"key":"1071_CR30","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","volume":"31","author":"A Pollack","year":"2013","unstructured":"Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized Trial of Hypofractionated External-Beam Radiotherapy for Prostate Cancer. J Clin Oncol. 2013;31:3860\u20133868.","journal-title":"J Clin Oncol"},{"key":"1071_CR31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","volume":"17","author":"S Aluwini","year":"2016","unstructured":"Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17:464\u2013474.","journal-title":"Lancet Oncol"},{"key":"1071_CR32","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","volume":"16","author":"S Aluwini","year":"2015","unstructured":"Aluwini S, Pos F, Schimmel E, Van Lin E, Krol S, Van Der Toorn PP, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol. 2015;16:274\u2013283.","journal-title":"Lancet Oncol"},{"key":"1071_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijrobp.2019.09.007","volume":"106","author":"KC de Vries","year":"2020","unstructured":"de Vries KC, Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, Incrocci L. Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial. Int J Radiat Oncol Biol Phys. 2020;106:108\u2013115.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR34","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ijrobp.2021.10.139","volume":"112","author":"F Sinzabakira","year":"2022","unstructured":"Sinzabakira F, Heemsbergen WD, Pos FJ, Incrocci L. Patient-reported outcomes in the acute phase of the randomized hypofractionated irradiation for Prostate Cancer (HYPRO) Trial. Int J Radiat Oncol. 2022;112:870\u2013879.","journal-title":"Int J Radiat Oncol"},{"key":"1071_CR35","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.jsxm.2016.08.012","volume":"13","author":"RC Wortel","year":"2016","unstructured":"Wortel RC, Pos FJ, Heemsbergen WD, Incrocci L. Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO Trial. J Sex Med. 2016;13:1695\u20131703.","journal-title":"J Sex Med"},{"key":"1071_CR36","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ijrobp.2016.01.031","volume":"95","author":"RC Wortel","year":"2016","unstructured":"Wortel RC, Incrocci L, Pos FJ, van der Heide UA, Lebesque JV, Aluwini S, et al. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. Int J Radiat Oncol Biol Phys. 2016;95:680\u2013689.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.radonc.2017.12.022","volume":"127","author":"EM Monninkhof","year":"2018","unstructured":"Monninkhof EM, Van Loon JWL, Van Vulpen M, Kerkmeijer LGW, Pos FJ, Haustermans K, et al. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial. Radiother Oncol. 2018;127:74\u201380.","journal-title":"Radiother Oncol"},{"key":"1071_CR38","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","volume":"20","author":"DH Brand","year":"2019","unstructured":"Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019;20:1531\u20131543.","journal-title":"Lancet Oncol"},{"key":"1071_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110089","volume":"193","author":"V Fonteyne","year":"2024","unstructured":"Fonteyne V, Berghen C, Van Praet C, Vanderstraeten B, Verbeke S, Villeirs G, et al. Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial. Radiother Oncol. 2024;193:110089.","journal-title":"Radiother Oncol"},{"key":"1071_CR40","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.ijrobp.2024.05.014","volume":"120","author":"DAS Toesca","year":"2024","unstructured":"Toesca DAS, Hartsell WF, DeWees TA, Chang JH, Laughlin BS, Voss MM, et al. Stereotactic body proton therapy versus conventionally fractionated proton therapy for early prostate cancer: a randomized, controlled, phase 3 trial. Int J Radiat Oncol. 2024;120:1377\u20131385.","journal-title":"Int J Radiat Oncol"},{"key":"1071_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","volume":"167","author":"VH Groen","year":"2022","unstructured":"Groen VH, van Schie M, Zuithoff NPA, Monninkhof EM, Kunze-Busch M, de Boer JCJ, et al. Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2022;167:127\u2013132.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"1071_CR42","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized Phase III Noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34:2325\u20132332.","journal-title":"J Clin Oncol"},{"key":"1071_CR43","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ijrobp.2017.07.044","volume":"99","author":"RC Wortel","year":"2017","unstructured":"Wortel RC, Heemsbergen WD, Smeenk RJ, Witte MG, Krol SDG, Pos FJ, et al. Local Protocol Variations for Image Guided Radiation Therapy in the Multicenter Dutch Hypofractionation (HYPRO) Trial: Impact of rectal balloon and mri delineation on anorectal dose and gastrointestinal toxicity levels. Int J Radiat Oncol Biol Phys. 2017;99:1243\u20131252.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00066-018-1395-y","volume":"195","author":"E Rammant","year":"2019","unstructured":"Rammant E, Ost P, Swimberghe M, Vanderstraeten B, Lumen N, Decaestecker K, et al. Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial. Strahlenther Onkol. 2019;195:393\u2013401.","journal-title":"Strahlenther Onkol"},{"key":"1071_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","volume":"112","author":"JE Leeman","year":"2022","unstructured":"Leeman JE, Chen Y-H, Catalano P, Bredfeldt J, King M, Mouw KW, et al. Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: a combined analysis of 23 prospective clinical trials. Int J Radiat Oncol Biol Phys. 2022;112:75\u201382.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR46","first-page":"00145","volume":"S1879-8500","author":"Le","year":"2024","unstructured":"Le, Gu\u00e9velou, Zilli J, Ferretti T, Beuzit L, De L, Hertogh O, Palumbo S, et al. Urinary organs-at-risk for prostate cancer external beam radiotherapy: contouring guidelines on behalf of the Francophone Group of Urological Radiation Therapy (GFRU). Pract Radiat Oncol. 2024;S1879-8500:00145\u20130.","journal-title":"Pract Radiat Oncol"},{"key":"1071_CR47","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1007\/s00345-023-04579-6","volume":"41","author":"J Le Guevelou","year":"2023","unstructured":"Le Guevelou J, Bosetti DG, Castronovo F, Angrisani A, de Crevoisier R, Zilli T. State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature. World J Urol. 2023;41:3287\u20133299.","journal-title":"World J Urol"},{"key":"1071_CR48","first-page":"100907","volume":"51","author":"JL Gu\u00e9velou","year":"2025","unstructured":"Gu\u00e9velou JL, Sargos P, Ost P, Alongi F, Arcangeli S, Berlin A, et al. Urethra-sparing prostate cancer radiotherapy: Current practices and future insights from an international survey. Clin Transl Radiat Oncol. 2025;51:100907.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1071_CR49","first-page":"00301","volume":"S0360-3016","author":"T Zilli","year":"2023","unstructured":"Zilli T, Jorcano S, Bral S, Symon Z, Rubio C, Bruynzeel AME, et al. Every-Other-Day Versus Once-a-Week Urethra-Sparing Prostate Stereotactic Body Radiation Therapy: 5-Year Results of a Randomized Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2023;S0360-3016:00301\u20132.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.radonc.2020.04.013","volume":"148","author":"X Pan","year":"2020","unstructured":"Pan X, Levin-Epstein R, Huang J, Ruan D, King CR, Kishan AU, et al. Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble machine learning. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020;148:181\u2013188.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"1071_CR51","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/COC.0000000000000586","volume":"42","author":"NA Iarrobino","year":"2019","unstructured":"Iarrobino NA, Gill B, Sutera PA, Kalash R, D\u2019 Ambrosio D, Heron DE. Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinical Trial. Am J Clin Oncol. 2019;42:856\u2013861.","journal-title":"Am J Clin Oncol"},{"key":"1071_CR52","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ijrobp.2023.10.015","volume":"118","author":"BK Neilsen","year":"2024","unstructured":"Neilsen BK, Ma TM, Akingbemi WO, Neylon J, Casado MC, Sharma S, et al. Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial. Int J Radiat Oncol Biol Phys. 2024;118:986\u2013997.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR53","first-page":"1201","volume":"30","author":"G Chetiyawardana","year":"2024","unstructured":"Chetiyawardana G, Chadwick E, Kordolaimi S, Sundar S. Bladder trigone sparing radiotherapy in prostate cancer treatment. Radiogr Lond Engl 1995. 2024;30:1201\u20131209.","journal-title":"Radiogr Lond Engl 1995"},{"key":"1071_CR54","volume":"45","author":"WL Ong","year":"2024","unstructured":"Ong WL, Allan Hupman M, Davidson M, Ruschin M, Detsky J, Liu S, et al. Urethra contouring on computed tomography urethrogram versus magnetic resonance imaging for stereotactic body radiotherapy in prostate cancer. Clin Transl Radiat Oncol. 2024;45:100722.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1071_CR55","doi-asserted-by":"crossref","unstructured":"Richardson M, Skehan K, Wilton L, Sams J, Samuels J, Goodwin J et al. Visualising the urethra for prostate radiotherapy planning. J Med Radiat Sci 2021;68:282\u2013288.","DOI":"10.1002\/jmrs.485"},{"key":"1071_CR56","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00345-025-05730-1","volume":"43","author":"J Le Gu\u00e9velou","year":"2025","unstructured":"Le Gu\u00e9velou J, Mathieu R, Peyrottes A, Dariane C, Murthy V, Nicosia L, et al. Tailoring prostate cancer external beam radiotherapy for patients with lower urinary tract symptoms. World J Urol. 2025;43:361.","journal-title":"World J Urol"},{"key":"1071_CR57","first-page":"00163","volume":"S2588-9311","author":"Le","year":"2023","unstructured":"Le, Guevelou J, Sargos P, Ferretti L, Supiot S, Pasquier D, Cr\u00e9hange G, et al. Sexual Structure Sparing for Prostate Cancer Radiotherapy: A Systematic Review. Eur Urol Oncol. 2023;S2588-9311:00163\u20133.","journal-title":"Eur Urol Oncol"},{"key":"1071_CR58","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.ijrobp.2009.04.094","volume":"76","author":"M Roach","year":"2010","unstructured":"Roach M, Nam J, Gagliardi G, El Naqa I, Deasy JO, Marks LB. Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys. 2010;76:S130\u2013134.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR59","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.eururo.2017.02.007","volume":"72","author":"DE Spratt","year":"2017","unstructured":"Spratt DE, Lee JY, Dess RT, Narayana V, Evans C, Liss A, et al. Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial. Eur Urol. 2017;72:617\u2013624.","journal-title":"Eur Urol"},{"key":"1071_CR60","doi-asserted-by":"crossref","unstructured":"Teunissen FR. Neurovascular-Sparing MR-Guided Adaptive Radiotherapy in Prostate Cancer; Defining the Potential Population for Erectile Function-Sparing Treatment. J Sex Med. 2022;19:1196\u20131200.","DOI":"10.1016\/j.jsxm.2022.04.006"},{"key":"1071_CR61","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.phro.2021.09.002","volume":"20","author":"FR Teunissen","year":"2021","unstructured":"Teunissen FR, Wortel RC, Hes J, Willigenburg T, de Groot-van Breugel EN, de Boer JCJ, et al. Adaptive magnetic resonance-guided neurovascular-sparing radiotherapy for preservation of erectile function in prostate cancer patients. Phys Imaging Radiat Oncol. 2021;20:5\u201310.","journal-title":"Phys Imaging Radiat Oncol"},{"key":"1071_CR62","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.ijrobp.2006.10.026","volume":"67","author":"P Kupelian","year":"2007","unstructured":"Kupelian P, Willoughby T, Mahadevan A, Djemil T, Weinstein G, Jani S, et al. Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1088\u20131098.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR63","doi-asserted-by":"publisher","unstructured":"Kusters J, Monshouwer R, Koopmans P, Wendling M, Brunenberg E, Kerkmeijer L et al. Prostate motion in magnetic resonance imaging-guided radiotherapy and its impact on margins. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al 2025. https:\/\/doi.org\/10.1007\/s00066-024-02346-z.","DOI":"10.1007\/s00066-024-02346-z"},{"key":"1071_CR64","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.ijrobp.2023.12.035","volume":"118","author":"J Neylon","year":"2024","unstructured":"Neylon J, Ma TM, Savjani R, Low DA, Steinberg ML, Lamb JM, et al. Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial. Int J Radiat Oncol Biol Phys. 2024;118:1181\u20131191.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR65","first-page":"25","volume":"30","author":"BS Teh","year":"2005","unstructured":"Teh BS, Dong L, McGary JE, Mai W-Y, Grant W, Butler EB. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer. Med Dosim Off J Am Assoc Med Dosim. 2005;30:25\u201330.","journal-title":"Med Dosim Off J Am Assoc Med Dosim"},{"key":"1071_CR66","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ijrobp.2005.05.010","volume":"63","author":"ENJT van Lin","year":"2005","unstructured":"van Lin ENJT, Hoffmann AL, van Kollenburg P, Leer JW, Visser AG. Rectal wall sparing effect of three different endorectal balloons in 3D conformal and IMRT prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:565\u2013576.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR67","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ijrobp.2011.07.028","volume":"83","author":"RJ Smeenk","year":"2012","unstructured":"Smeenk RJ, Louwe RJW, Langen KM, Shah AP, Kupelian PA, van Lin ENJT, et al. An endorectal balloon reduces intrafraction prostate motion during radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:661\u2013669.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR68","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejmp.2019.04.008","volume":"61","author":"M Jaccard","year":"2019","unstructured":"Jaccard M, Lamanna G, Dubouloz A, Rouzaud M, Miralbell R, Zilli T. Dose optimization and endorectal balloon for internal pudendal arteries sparing in prostate SBRT. Phys Med. 2019;61:28\u201332.","journal-title":"Phys Med"},{"key":"1071_CR69","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/jmrs.238","volume":"64","author":"L Wilton","year":"2017","unstructured":"Wilton L, Richardson M, Keats S, Legge K, Hanlon M-C, Arumugam S, et al. Rectal protection in prostate stereotactic radiotherapy: a retrospective exploratory analysis of two rectal displacement devices. J Med Radiat Sci. 2017;64:266\u2013273.","journal-title":"J Med Radiat Sci"},{"key":"1071_CR70","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.radonc.2019.06.018","volume":"140","author":"Y Alayed","year":"2019","unstructured":"Alayed Y, Quon H, Cheung P, Chu W, Chung HT, Vesprini D, et al. Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials. Radiother Oncol. 2019;140:105\u2013109.","journal-title":"Radiother Oncol"},{"key":"1071_CR71","first-page":"02688","volume":"S0302-2838","author":"AU Kishan","year":"2024","unstructured":"Kishan AU, Lamb JM, Wilhalme H, Casado M, Chong N, Zello L, et al. Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial. Eur Urol. 2024;S0302-2838:02688\u20135.","journal-title":"Eur Urol"},{"key":"1071_CR72","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/130579","volume":"2012","author":"DW Litzenberg","year":"2012","unstructured":"Litzenberg DW, Balter JM, Hadley SW, Hamstra DA, Willoughby TR, Kupelian PA, et al. Prostate intrafraction translation margins for real-time monitoring and correction strategies. Prostate Cancer. 2012;2012:130579.","journal-title":"Prostate Cancer"},{"key":"1071_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.14179","volume":"25","author":"C Onal","year":"2024","unstructured":"Onal C, Efe E, Bozca R, Yavas C, Yavas G, Arslan G. The impact of margin reduction on radiation dose distribution of ultra-hypofractionated prostate radiotherapy utilizing a 1.5-T MR-Linac. J Appl Clin Med Phys. 2024;25:e14179.","journal-title":"J Appl Clin Med Phys"},{"key":"1071_CR74","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/0284186X.2020.1821090","volume":"60","author":"L Nicosia","year":"2021","unstructured":"Nicosia L, Sicignano G, Rigo M, Figlia V, Cuccia F, De Simone A, et al. Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy. Acta Oncol Stockh Swed. 2021;60:215\u2013221.","journal-title":"Acta Oncol Stockh Swed"},{"key":"1071_CR75","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s11547-023-01624-7","volume":"128","author":"L Nicosia","year":"2023","unstructured":"Nicosia L, Mazzola R, Rigo M, Giaj-Levra N, Pastorello E, Ricchetti F, et al. Linac-based versus MR-guided SBRT for localized prostate cancer: a comparative evaluation of acute tolerability. Radiol Med. 2023;128:612\u2013618.","journal-title":"Radiol Med"},{"key":"1071_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110043","volume":"190","author":"L Nicosia","year":"2024","unstructured":"Nicosia L, Ravelli P, Rigo M, Giaj-Levra N, Mazzola R, Pastorello E, et al. Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2024;190:110043.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"1071_CR77","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.radonc.2021.12.037","volume":"167","author":"TM Ma","year":"2022","unstructured":"Ma TM, Neylon J, Casado M, Sharma S, Sheng K, Low D, et al. Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: A post-hoc analysis of a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2022;167:203\u2013210.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"1071_CR78","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/j.clon.2022.03.022","volume":"34","author":"SE Alexander","year":"2022","unstructured":"Alexander SE, McNair HA, Oelfke U, Huddart R, Murray J, Pathmanathan A, et al. Prostate Volume Changes during Extreme and Moderately Hypofractionated Magnetic Resonance Image-guided Radiotherapy. Clin Oncol R Coll Radiol G B. 2022;34:e383\u2013e391.","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"1071_CR79","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ijrobp.2025.01.021","volume":"122","author":"TM Janssen","year":"2025","unstructured":"Janssen TM, van der Bijl E, Dassen MG, van der Heide UA. Toward the End of Planning Target Volume Margins With Online Adaptive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2025;122:554\u2013557.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR80","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","volume":"97","author":"DA Hamstra","year":"2017","unstructured":"Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, et al. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys. 2017;97:976\u2013985.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR81","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1001\/jamaoncol.2022.7592","volume":"9","author":"NF Mariados","year":"2023","unstructured":"Mariados NF, Orio PF, Schiffman Z, Van TJ, Engelman A, Nurani R, et al. Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial. JAMA Oncol. 2023;9:511\u2013518.","journal-title":"JAMA Oncol"},{"key":"1071_CR82","first-page":"36","volume":"29","author":"M Miszczyk","year":"2025","unstructured":"Miszczyk M, Stando R, Francolini G, Zamboglou C, Cadenar A, Suleja A, et al. Perirectal spacers in radiotherapy for prostate cancer - a systematic review and meta-analysis. Contemp Oncol Poznan Pol. 2025;29:36\u201344.","journal-title":"Contemp Oncol Poznan Pol"},{"key":"1071_CR83","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","volume":"92","author":"N Mariados","year":"2015","unstructured":"Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, et al. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015;92:971\u2013977.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1071_CR84","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20200433","volume":"94","author":"ME Hwang","year":"2021","unstructured":"Hwang ME, Mayeda M, Shaish H, Elliston CD, Spina CS, Wenske S, et al. Dosimetric feasibility of neurovascular bundle-sparing stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer to preserve erectile function. Br J Radiol. 2021;94:20200433.","journal-title":"Br J Radiol"},{"key":"1071_CR85","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.prro.2017.07.008","volume":"8","author":"DA Hamstra","year":"2018","unstructured":"Hamstra DA, Mariados N, Sylvester J, Shah D, Gross E, Hudes R, et al. Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal\/prostate spacer: Secondary analysis of a phase 3 trial. Pract Radiat Oncol. 2018;8:e7\u2013e15.","journal-title":"Pract Radiat Oncol"},{"key":"1071_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1143716","volume":"13","author":"PV Nguyen","year":"2023","unstructured":"Nguyen PV, Donneaux B, Louis C, Bodgal Z, Philippi S, Biver S, et al. Stereotactic focal radiotherapy as an alternative treatment for low-risk prostate cancer: Results of a single-arm monocenter Phase-II trial. Front Oncol. 2023;13:1143716.","journal-title":"Front Oncol"},{"key":"1071_CR87","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00066-021-01832-y","volume":"197","author":"P Nguyen","year":"2021","unstructured":"Nguyen P, Harz\u00e9e L, Retif P, Joseph S, Vogin G, Nickers P. Prospective validation of stringent dose constraints for prostatic stereotactic radiation monotherapy: results of a single-arm phase II toxicity-oriented trial. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al. 2021;197:1001\u20131009.","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"key":"1071_CR88","doi-asserted-by":"crossref","unstructured":"De Cock L, Draulans C, Pos FJ, Isebaert S, De Roover R, van der Heide UA et al. From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. Radiother Oncol J Eur Soc Ther Radiol Oncol 2023;185:109713.","DOI":"10.1016\/j.radonc.2023.109713"},{"key":"1071_CR89","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1200\/jco.2015.33.7_suppl.6","volume":"33","author":"HC Quon","year":"2015","unstructured":"Quon HC, Ong A, Cheung P, Chu W, Chung HT, Vesprini D, et al. PATRIOT Trial: Randomized phase II study of prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time. J Clin Oncol. 2015;33:6\u20136.","journal-title":"J Clin Oncol"},{"key":"1071_CR90","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.radonc.2020.04.039","volume":"149","author":"Y Alayed","year":"2020","unstructured":"Alayed Y, Quon H, Ong A, Cheung P, Chu W, Chung H, et al. Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT). Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020;149:8\u201313.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"1071_CR91","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.radonc.2021.12.040","volume":"167","author":"AU Kishan","year":"2022","unstructured":"Kishan AU, Marco N, Schulz-Jaavall M-B, Steinberg ML, Tran PT, Juarez JE, et al. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Radiother Oncol. 2022;167:226\u2013232.","journal-title":"Radiother Oncol"},{"key":"1071_CR92","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1158\/1078-0432.CCR-24-3951","volume":"31","author":"AU Kishan","year":"2025","unstructured":"Kishan AU, McGreevy K, Valle L, Steinberg M, Neilsen B, Casado M, et al. Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2025;31:2530\u20132538.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1071_CR93","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/bjr\/tqaf056","volume":"98","author":"D Azria","year":"2025","unstructured":"Azria D, Haviland JS, Brengues M, Griffin C, Moquet J, Barnard S, et al. Radiation-induced lymphocyte apoptosis and chromosomic aberrations for prediction of toxicities in patients undergoing radical radiotherapy for breast or prostate cancers. Br J Radiol. 2025;98:929\u2013937.","journal-title":"Br J Radiol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01071-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01071-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01071-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:03:53Z","timestamp":1786662233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01071-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1071"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01071-7","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}